How to lower your cholesterol without going on statins
You can lower your cholesterol without statins through diet, exercise, weight and smoking changes and the way to know whether it's working is to measure Apo B before you start and again a few months in.
Whether medication is right for you is a conversation with your physician. Plenty of people have a risk profile where a statin is the sensible call. But if you and your doctor have decided to try lifestyle changes first, or to run them alongside, the question becomes how you tell whether they're actually moving anything.
That's the part most people are missing. Cholesterol changes are invisible; you can't feel them. Without a before-and-after number, you're guessing.
What actually moves the numbers
| Change | What the evidence shows |
|---|---|
| Oat fibre | About 3 g of beta-glucan oat fibre lowers LDL cholesterol by roughly 8% |
| Plant sterols | An average 2 g/day produced an 8.8% reduction in LDL |
| Psyllium | 7 g/day of psyllium fibre helps lower LDL |
| Barley | 3 g of barley beta-glucan; LDL reductions up to about 8.5% |
| Swapping saturated for unsaturated fat | LDL falls roughly 0.4% to 2.8% for every gram replaced |
| Aerobic exercise | Modest lipid improvements; Canadian guidelines recommend 150 min/week mainly for overall risk reduction |
| Weight loss, stopping smoking | Both improve the wider risk profile well beyond the lipid numbers |
Combined, these add up to more than people expect. In a Canadian trial, a diet built around plant sterols, soy protein, viscous fibres and almonds lowered LDL by 28.6% in four weeks, close to what a statin achieved in the same study.
Where non-statin medications fit
Ezetimibe and PCSK9 inhibitors both lower cholesterol through different mechanisms than statins. It's worth being precise about how Canadian guidelines position them: as add-on therapies for people who remain above target despite the maximum statin dose they can tolerate, or who have familial hypercholesterolemia. They're not framed as replacements. What suits you is a conversation for your physician.
What to measure, and when
Apo B is the marker to track. It counts the actual number of atherogenic particles in your blood. Every LDL, VLDL, IDL and Lp(a) particle carries exactly one Apo B molecule, which makes it a direct count rather than an estimate.
When to retest. If you've changed something and want to know whether it worked, BC's provincial guideline suggests following up with an Apo B or non-HDL-C after 3 to 6 months. That's a different question from routine risk screening, which runs on a much longer cycle: every 5 years at low risk, every 1 to 3 years at high risk.
Numia's Cardiac panel measures Apo B alongside Lp(a), hs-CRP, a full lipid profile and VLDL, from a single draw at your home.
Sources6 references
- Guidelines and Protocols Advisory Committee. (2023). Cardiovascular disease – Primary prevention. BC Guidelines. British Columbia Ministry of Health. View guideline
- Health Canada. (2010). Plant sterols and blood cholesterol lowering: Summary of assessment of a health claim.canada.ca/en/health-canada
- Health Canada. (2010). Summary of Health Canada's assessment of a health claim about oat products and blood cholesterol lowering.canada.ca/en/health-canada
- Health Canada. (2012). Summary of Health Canada's assessment of a health claim about the replacement of saturated fat with mono- and polyunsaturated fat and blood cholesterol lowering.canada.ca/en/health-canada
- Jenkins, D. J., Kendall, C. W., Marchie, A., Faulkner, D. A., Wong, J. M., de Souza, R., Emam, A., Parker, T. L., Vidgen, E., Lapsley, K. G., Trautwein, E. A., Josse, R. G., Leiter, L. A., & Connelly, P. W. (2003). Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. JAMA, 290(4), 502–510.
- Pearson, G. J., Thanassoulis, G., Anderson, T. J., Barry, A. R., Couture, P., Dayan, N., Francis, G. A., Genest, J., Grégoire, J., Grover, S. A., Gupta, M., Hegele, R. A., Lau, D., Leiter, L. A., Leung, A. A., Lonn, E., Mancini, G. B. J., Manjoo, P., McPherson, R., … Wray, W. (2021). 2021 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults. Canadian Journal of Cardiology, 37(8), 1129–1150. https://doi.org/10.1016/j.cjca.2021.03.016
Last updated September 2, 2026
